Biotech company OMass Therapeutics, which focuses on discovering medicines for complex biological systems like membrane proteins and internal structures, announced the appointment of Carol A. Schafer as a non-executive director and head of the audit committee. Carol has more than 25 years of experience in healthcare investment banking, equity markets, corporate finance, and business development. She currently serves on the boards of several public companies, including Insmed Incorporated, Immunome, Inc., Kura Oncology, Inc., and Repare Therapeutics Inc.
Health Technology Insights: OrbiMed Raises $1.86 Billion for Healthcare Royalty and Credit Fund V
In her past, she held board positions at Five Prime Therapeutics, which Amgen bought for $1.9 billion in 2021, and Idera Pharmaceuticals before its merger in 2022. Her career has primarily focused on equity capital markets, notably at Wells Fargo Securities from 2007 to 2018, where she served as Vice Chair. Prior to that, she held various senior roles at J.P. Morgan, culminating as Managing Director in the Equity Capital Markets division. Carol obtained her MBA from New York University’s Stern School of Business and holds a Bachelor of Arts from Boston College.
Health Technology Insights: Delta Development Closes Series A3, Leads Prehospital Blood
Carol expressed her thoughts on her new position, stating, “I’m honored to join the Board and help with OMass’s mission to create top-tier small molecules for underserved areas in endocrinology and immunology. I’m excited to collaborate with the Board and support the company as they progress toward the clinic and prepare for their next phase of growth.”
Jim Geraghty, Chairman of the Board at OMass Therapeutics, added, “Carol’s extensive background in healthcare investment banking and biotech board experience will be crucial as OMass transitions into a clinical-stage company. I believe her strategic wisdom and understanding of equity markets will be a significant advantage to the company.”
“We’re pleased to welcome her to the Board and as our new audit committee chair,” he concluded.
Health Technology Insights: EVERSANA Launches AI Life Sciences Agency on Google Cloud
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
